MEDNAX, Inc. (NYSE:MD)—a Sunrise, FL-based provider of newborn hearing screen services—announced its launch of the MEDNAX Audiology Institute, which the company says will help promote innovation and collaboration across all aspects of pediatric hearing loss—early detection, diagnosis, and treatment—as well as quality and access to care.
Pediatrix Medical Group, Inc, a MEDNAX subsidiary, provides maternal-fetal, newborn, and pediatric subspecialty services and, through the Pediatrix Newborn Hearing Screen Program, MEDNAX reportedly screens more than 850,000 newborns in over 30 states and over 430 hospitals annually. To date, the program has reportedly screened more than seven million babies nationwide.
According to MEDNAX, the development of the Audiology Institute was fueled not only by MEDNAX’s hearing screen success, but the need for a more comprehensive, collaborative, and integrated approach to advance the treatment of pediatric hearing loss. Early identification and timely audiology assessment is said to provide “a crucial opportunity” for infants to receive prompt intervention, which can dramatically increase their quality of life.
“We look forward to partnering with organizations that have a shared passion for leading improvements along the pediatric hearing loss care continuum,” said Jillian Gerstenberger, AuD, MBA, associate director of research, education, quality, and safety for hearing screen/clinical manager, Newborn Hearing Screen Program. “As we address the current challenges impacting the field of pediatric hearing health, we look to enhance the future of care through collaborations with other likeminded organizations, leveraging telehealth, precision medicine, and artificial intelligence to continue driving improvements in early identification, diagnosis, and intervention for all patients.”